Last edition
News about "HIV drug development"
US FDA Accepts Gilead's Once-Weekly Yeztugo for HIV Prevention
Gilead’s investigational once-weekly oral HIV prevention pill Yeztugo has been accepted for US FDA review, supported by strong clinical data showing high efficacy of lenacapavir in preventing HIV across 2 clinical trials. The therapy could become the first long-acting oral option for HIV prevention.
HIV Drug Development | 16/06/2026 | By News Bureau
Gilead and Merck Report Positive Phase 3 Results for Weekly HIV Pill
Gilead and Merck reported positive phase 3 results for the investigational once-weekly oral HIV therapy islatravir/lenacapavir, which has the potential to become the first approved long-acting weekly oral treatment for people living with HIV.
HIV Drug Development | 09/06/2026 | By News Bureau | 111
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy